دورية أكاديمية
817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
| العنوان: | 817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047 |
|---|---|
| المؤلفون: | Hodi, F.S., Tawbi, H.A., Lipson, E.J., Schadendorf, D., Ascierto, P.A., Matamala, L.A., Salman, P., Gutierrez, E.C., Rutkowski, P., Gogas, H.J., Lao, C.D., Menezes, J., Dalle, S., Arance Fernandez, A.M., Grob, J.J., Keidel, S., Rodriguez, S., Wang, P., Dolfi, S., Long, G.V. |
| المصدر: | Annals of Oncology ; volume 33, page S920-S921 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Oncology, Hematology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2022.07.943 |
| الإتاحة: | https://doi.org/10.1016/j.annonc.2022.07.943Test https://api.elsevier.com/content/article/PII:S0923753422027946?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S0923753422027946?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://www.elsevier.com/open-access/userlicense/1.0Test/ |
| رقم الانضمام: | edsbas.BF0211AF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2022.07.943 |
|---|